Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Energy price falls spark drop in German and Spanish inflation
    • ‘Total distrust’: rise of the Russian informers
    • Sheikh Mohammed bin Zayed names his son crown prince of Abu Dhabi
    • Russia detains Wall Street Journal reporter on suspicion of spying
    • Ultranationalist Israeli minister outlines plans for new national guard
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • How rising interest rates are exposing bank weaknesses
      • Revolut board frustrated by fintech company’s response to audit warning
      • London loses sole lead as world’s top financial centre
      • Walt Disney ousts Marvel chair Isaac Perlmutter after he clashed with CEO Bob Iger
      • Boutique adviser Centerview beats Wall Street banks in deal rankings
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • How rising interest rates are exposing bank weaknesses
      • Live news: Banks up usage of Fed’s new lending facility to $65bn
      • Revolut board frustrated by fintech company’s response to audit warning
      • London loses sole lead as world’s top financial centre
      • European real estate stocks hammered by banking turmoil
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • Fox News’ populist mask has slipped
      • Multiple red flags are not yet slowing the generative AI train
      • Prepare for a multipolar currency world
      • Biden’s awkward democracy summit
      • ‘Succession’ triumph may mark a bookend for the ‘peak TV’ era
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Matthew Desmond: ‘America does so much more to subsidise affluence than alleviate poverty’
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • I used AI to bet on horse-racing. Here’s what happened
      • It’s morally repugnant, but isolationism on Ukraine makes some sense
      • The Zara woman: an exclusive interview with Marta Ortega Pérez
      • The Noble Rot guide to Burgundy
      • The big new trends from Watches and Wonders 2023
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Coronavirus treatment

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Monday, 27 March, 2023
      BioNTech
      BioNTech forecasts slump in sales as demand for Covid jab wanes

      Expected fall highlights challenges for pharmaceutical companies that experienced pandemic windfall

    • Wednesday, 15 March, 2023
      Taiwan
      Taiwan loses diplomatic ally as Honduras confirms link to China

      Central American nation was one of Taipei’s last partners in Washington’s backyard

    • Tuesday, 14 March, 2023
      Covid-19 vaccines
      Pfizer’s revised EU Covid vaccine contract meets resistance

      Four member states including Poland say amended deal is not ‘fair solution’ to surplus of shots

    • Tuesday, 7 March, 2023
      Covid-19 vaccines
      UK spring Covid boosters will target elderly and vulnerable

      Health secretary confirms acceptance of advice from expert committee to ‘bridge the gap’ to autumn

    • Friday, 3 March, 2023
      Healthcare
      US health and science bodies unite to fight misinformation ‘infodemic’

      Fifty organisations form coalition to counter dangerous falsehoods and rebuild trust in science

    • Friday, 24 February, 2023
      Special ReportHealth at Work
      Why Long Covid rehab must be very, very slow

      Employers advised they need to offer more time and flexibility compared with other illnesses

    • Tuesday, 21 February, 2023
      Pfizer Inc
      Pfizer pins hopes on record pipeline to recover from post-Covid hangover

      Pharma group is launching 19 drugs over the next 18 months to counteract a sharp fall in sales from pandemic highs

    • Wednesday, 15 February, 2023
      Jayasree Iyer
      Poor countries desperately need better access to generic medicines

      Manufacturers showed during the pandemic that they can deliver low-cost treatments at scale

    • Wednesday, 15 February, 2023
      Covid-19 vaccines
      CanSino says vaccine demand down after China’s mass Covid infections

      Pharma group hopes for approval of mRNA vaccine for booster shots

    • Thursday, 9 February, 2023
      AstraZeneca PLC
      AstraZeneca chief says industry should not pay for NHS Covid costs

      Pascal Soriot criticises pricing agreement with UK health service

    • Sunday, 29 January, 2023
      Drugs research
      RQ Bio partners with AstraZeneca in Covid antibody fight

      UK biotech racing to keep antibody up to date with latest variants

    • Thursday, 26 January, 2023
      UK universities
      Lack of clinical academics threatens NHS research and teaching, say peers

      Shortage of doctors with university posts is putting health service on ‘dangerous precipice’

    • Tuesday, 24 January, 2023
      Kate Bingham
      Britain is losing its chance to become a life sciences superpower

      Short-termism and suspicion in parts of government risk our valuable future in precision medicine

    • Monday, 23 January, 2023
      News in-depth
      Rural China runs short of Covid drugs over lunar new year holiday

      Officials row with Pfizer over price as villages struggle to obtain antiviral medication

    • Friday, 13 January, 2023
      Wes Streeting
      Only radical thinking can find a long-term cure for the NHS

      Starting with primary care, investment combined with modernisation can deliver better outcomes for patients

    • Thursday, 12 January, 2023
      EU economy
      EU draws up plans to stockpile scarce medicines

      Effort to improve health supply chain issues that have led to Greece imposing an export ban on drugs

    • Tuesday, 10 January, 2023
      Covid-19 vaccines
      Chinese bank tries to entice wealthy customers with mRNA vaccines

      Hong Kong-based lender seeks to cater to mainlanders’ demand for western jabs

    • Tuesday, 10 January, 2023
      Coronavirus pandemic
      China’s Covid patients face medical debt crisis as insurers refuse coverage

      Narrow definition of cases leaves claimants on the hook after state-backed policies drop free care

    • Monday, 9 January, 2023
      CureVac GmbH
      Covid vaccine makers CureVac and Novavax appoint new chiefs

      Pharmaceutical groups to part ways with longstanding executives

    • Monday, 9 January, 2023
      InterviewPharmaceuticals sector
      SK Bioscience says ‘national pride’ prevents China from accepting foreign Covid jabs

      South Korean vaccine maker looks elsewhere to expand overseas business

    • Friday, 6 January, 2023
      Pharmaceuticals sector
      US approves Alzheimer’s drug that slows rate of cognitive decline

      High price of treatment and restrictions on medicine developed by Eisai and Biogen will limit patient access initially

    • Friday, 6 January, 2023
      Covid-19 vaccines
      New Chinese mRNA Covid vaccine shows positive early results

      Jab developed by CanSinoBio could help nation grappling with a wave of infection

    • Friday, 6 January, 2023
      Coronavirus economic impact
      Ambulances left waiting for record times as ‘twindemic’ hits UK

      Covid and flu hospitalisations soar over Christmas as emergency service delays worsen

    • Thursday, 5 January, 2023
      ExplainerCoronavirus pandemic
      How serious is the threat of new Covid-19 variants?

      A surge in cases after China lifted restrictions has sparked concerns that a dangerous new strain could emerge

    • Tuesday, 3 January, 2023
      Covid-19 vaccines
      EU offers free Covid-19 vaccines to China to help curb outbreak

      Beijing rejects Brussels’ offer, citing full control of situation

    Previous page You are on page 1 Next page

    Recommended

    Covid-19 vaccines
    Covid-19 vaccine tracker: Lowest-income countries lag further behind rest of the world
    Covid-19 vaccines
    Covid vaccine development: The shots available and the doses administered
    Covid-19 vaccines
    In graphics: the UK vaccine supply chain
    Coronavirus: free to read
    Coronavirus tracker: the latest figures as countries fight the Covid-19 resurgence

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In